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Background: N-linked protein glycosylation plays an important role in various biological processes, including
protein folding and trafficking, and cell adhesion and signaling. The acquisition of a novel N-glycosylation site may
have significant effect on protein structure and function, and therefore, on the phenotype.
Results: We analyzed the human glycoproteome data set (2,534 N-glycosylation sites in 1,027 proteins) and
identified 112 novel N-glycosylation sites in 91 proteins that arose in the human lineage since the last common
ancestor of Euarchonta (primates and treeshrews). Three of them, Asn-196 in adipocyte plasma membrane-associated
protein (APMAP), Asn-91 in cluster of differentiation 166 (CD166/ALCAM), and Asn-76 in thyroglobulin, are
human-specific. Molecular evolutionary analysis suggested that these sites were under positive selection during
human evolution. Notably, the Asn-76 of thyroglobulin might be involved in the increased production of
thyroid hormones in humans, especially thyroxine (T4), because the removal of the glycan moiety from this
site was reported to result in a significant decrease in T4 production.
Conclusions: We propose that the novel N-glycosylation sites described in this study may be useful candidates
for functional analyses to identify innovative genetic modifications for beneficial phenotypes acquired in the
human lineage.
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N-linked glycosylation of the Asn residue in the consen-
sus motif Asn-X-Ser/Thr, where X is any amino acid except
Pro, is one of the most well-studied protein posttransla-
tional modifications (PTMs) [1]. N-glycosylation, which
mainly occurs in secreted or cell membrane proteins, plays
important roles in protein folding, quality control, and
trafficking [2], as well as cell adhesion and signalling [3,4].
The emergence of a new N-glycosylation site may alter
protein function either positively or negatively. For
example, missense mutations in factor VIII created novel
N-glycosylation sites that cause severe hemophilia A [5].
Similarly, a missense mutation in the interferon γ recep-
tor 2 induces novel N-glycosylation, which results in a
Mendelian susceptibility to mycobacterial disease [6,7].
The abolishment of N-glycosylation sites often causes
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unless otherwise stated.proper N-glycosylation is crucial for normal protein
function [8,9]. A proteome-wide analysis of nonsynon-
ymous single-nucleotide variations in the N-glycosylation
motifs of human genes showed that more than 1,000
human proteins had either lost or gained N-glycosylation
sites due to missense substitutions, some of which may be
implicated in diseases [10].
The gain of new N-glycosylation sites during evolution
may affect the structure and molecular function of pro-
teins; when these novel modifications confer beneficial
traits, they will be fixed during evolution. Previously, we
identified a large variety of genetic changes that could
have been involved in the acquisition of human traits, in-
cluding gene inactivation [11,12], exon evolution [13,14],
and gains of phosphorylation or ubiquitylation [15,16].
Therefore, it would be of great interest to collect informa-
tion on novel N-glycosylation sites that arose during hu-
man evolution, as the sites might have been involved in
the development of some human phenotypes.
In order to study associations between the acquisition
of an N-glycosylation site and its phenotypic outcome, aal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Overall procedure for identifying gains of novel
N-glycosylation sites during human evolution. Computational
screening and manual inspection were employed to identify the
acquisition of novel N-glycosylation sites in human proteins
during human evolution.
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lian orthologous protein sequence data are required.
Recent developments and advances in various high-
throughput proteomics techniques for N-glycoproteome
identification using immunoaffinity subtraction, hydrazide
chemistry, and mass spectrometry have made it possible
to access massive amounts of N-glycosylation site data
from human proteomes [17-19]. These data are available
at the UniProt database (http://www.uniprot.org), which
is a universal protein sequence database, as well as some
specialized PTM databases such as PHOSIDA (http://
www.phosida.com/) [20].
Since human genome sequences were completed [21,22],
a large amount of nucleotide and protein sequence data
have become available not only from humans but also
from many other organisms. Comparative sequence data,
including alignments of mammalian orthologous protein
sequences, are available at the University of California
Santa Cruz (UCSC) Genome Browser Database (http://
genome.ucsc.edu) [23].
In this study, a bioinformatics method was devised to
identify novel N-glycosylated Asn residues that are lo-
cated in the consensus motif Asn-X-Ser/Thr and arose
during human evolution after the Euarchonta lineage di-
verged from the Glires lineage. Both a comprehensive lit-
erature survey and extensive data mining were conducted
to examine the possible functional implications of novel
N-glycosylation sites, especially in cases of human-specific
gains.
Results
Identification of novel N-glycosylation sites acquired
during human evolution and determination of the timing
of acquisition
We developed a bioinformatics procedure to identify the
acquisition by proteins of the N-glycosylation motif
Asn-X-Ser/Thr, where the Asn residue was experimen-
tally verified to be N-glycosylated, during human evolu-
tion (Figure 1). A novel N-glycosylation site can arise by
the emergence of not only an Asn residue but also a Ser
or Thr residue to form the consensus motif [24]. The
overall procedure devised in this study is similar to that
used to identify novel ubiquitylation sites in a previous
study [16]. Initially, there were 2,534 experimentally verified
human N-glycosylation sites from 1,027 proteins in the
UniProt database, and 57,289 orthologous protein sequence
alignments from 62 mammalian species, including spe-
cies from Euarchonta, Glires, Laurasiatheria, Afrotheria,
Xenarthra, Marsupialia, and Monotremata, extracted from
the UCSC “multiz100way” data [25] (see Additional file 1
for the list of mammalian species). These data were ana-
lyzed to collect N-glycosylation sites in human proteins
that newly appeared during the evolution from the com-
mon ancestor, Euarchonta (primates and treeshrews); asthe result, 112 novel N-glycosylation sites from 91 pro-
teins were identified. A summary of the results are pre-
sented in Additional file 2, and detailed alignments are
provided in Additional file 3. Of the 91 proteins, one pro-
tein (CFH) had acquired four N-glycosylation sites (Nos.
28 to 31 in Additional file 2 and Additional file 3; two pro-
teins (PTPRC and PTPRJ) had acquired three sites each
(Nos. 85 to 87, and 88 to 90, respectively); 14 proteins had
acquired two sites each; and the remaining 74 proteins
had acquired one site each. Figure 2 shows the number of
the N-glycosylation sites that are shared by each of the
Euarchonta clades along the human lineage: humans,
three; ancestor of humans and chimpanzees, two; African
great apes, 10; great apes, four; apes, 12; catarrhines, 16;
simians, 45; primates, 15; and euarchonts, 5.
Most of the novel N-glycosylation sites were gener-
ated by the emergence of an Asn residue in an existing
X-X-Ser/Thr motif. However, in some cases, the emer-
gence of a Ser or a Thr residue in an Asn-X-X sequence
created a novel N-glycosylation site: for example, a change
from Asn-Glu-Ile to Asn-Glu-Thr generated a novel
N-glycosylation site at Asn-911 in complement factor H
(CFH) in apes (No. 30 in Additional file 3).
Of the 112 novel N-glycosylation sites, three sites in three
proteins were human specific (Table 1 and Figure 3); there-
fore, these Asn residues subject to the N-glycosylation
evolved and were fixed in human proteins after the
Figure 2 Timing of acquisition and numbers of novel N-glycosylation sites in the human lineage. Numbers of novel N-glycosylation sites
acquired in the human lineage of the mammalian phylogenetic tree are shown. The number of sites acquired is shown on each branch where
the N-glycosylation site consensus motif emerged in the ancestor of the corresponding clade.
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Asn-196 in adipocyte plasma membrane-associated pro-
tein (APMAP), Asn-91 in cluster of differentiation 166
(CD166), and Asn-76 in thyroglobulin.
Human-specific N-glycosylation site Asn-196 in APMAP
The human APMAP (also known as C20orf3) has two
N-glycosylation sites: Asn-160 and Asn-196, the latter of
which is human specific: almost all the other mammals
examined have a Lys residue at this position (Figure 3A).
Full-length protein and coding sequences of APMAP
orthologs were determined from human, chimpanzee,
gorilla, orangutan, gibbon, and rhesus macaque genomes
(see Methods section for details). Multiple alignment of
these proteins showed that human APMAP protein has
two human-specific amino acid changes, Val-100 and
Asn-196, where all the other five primates have Ile and Lys,
respectively (Additional file 4). The Asn-196 is a human-
specific N-glycosylation site.
To test if the APMAP protein has been under positive
selection during human evolution, the ratios of nonsy-
nonymous to synonymous rates (dN/dS, ω) across differ-
ent branches and sites of the selected primate phylogeny
were estimated [26-28]. First, we used “branch models”,
M0 (one ω ratio for all branches), free ratio (one ω ratio
for each branch), and two ratio (ω1 for the human
branch and ω0 for other branches) models (Table 2 andTable 1 Proteins with human-specific N-glycosylation sites
Noa Gene UniProt ID Position Sequence
5 ALCAM CD166_HUMAN 91 DDVPEYKD
8 APMAP APMAP_HUMAN 196 LSSETPIEGK
105 TG THYG_HUMAN 76 DGRSCWCV
aThe number corresponds to that in Additional files 1 and 2.
bThe N-glycosylation motif is in bold.Additional file 4). The likelihood ratio test (LRT) com-
paring M0 (one ratio) and free ratio model was not sig-
nificant. However, the LRT comparing M0 and two ratio
model was highly significant (P = 0.006943), suggesting
the human APMAP has evolved at different rate com-
pared to other primates. The estimated dN and dS rates
for the human branch using two ratio model were
0.0024 and 0.0000 (see Additional file 4 for details), re-
spectively, indicating possible accelerated nonsynonymous
substitution during human evolution. Next, we used
“branch-site models”, model A (ω ratio is left to vary) and
null model A (ω ratio is fixed to 1), to infer positively se-
lected sites in human APMAP. The two aforementioned
human-specific amino acid positions, Val-100 and Asn-
196, were detected to be under positive selection with
overall probability of 0.828 and 0.953, respectively, using
the Bayes empirical Bayes (BEB) test [29]. However, the
LRT comparing model A and null model A was not sig-
nificant. Although it is statistically insignificant, the acqui-
sition of Asn-196 and its subsequent N-glycosylation
might have a significant effect on the structure and func-
tion of APMAP in humans.
APMAP is an adipocyte plasma membrane-associated
protein, which is induced during adipocyte differenti-
ation [30]. It is ubiquitously expressed in human embry-
onic and adult tissues, with the highest levels in liver,
placenta, and kidney [31]. APMAP may exhibit calcium-b Protein
RLNLSENYTLSI CD166 antigen
NMSFVNDLTV Adipocyte plasma membrane-associated protein
GANGSEVLGSRQ Thyroglobulin
Figure 3 Multiple sequence alignments of human-specific N-glycosylation sites. The human-specific N-glycosylation modification sites and
the surrounding regions for APMAP (A), CD166 (B), and thyroglobulin (C) proteins are presented. The N-glycosylation consensus sequences are
highlighted in cyan. An adjacent N-glycosylation site (Asn-95) that is found in CD166 and is well conserved among mammals is indicated by plus signs
(+++). The residues that are identical to those in the human sequence are indicated by dots (.). Dashes (−) denote alignment gaps. In some species,
sequences were not determined. hum, humans; hac, humans and chimpanzees; aga, African great apes; gra, great apes; ape, apes; cat, catarrhines; sim,
simians; pri, primates; eua, Euarchonta; gli, Glires; lau, Laurasiatheria; afr, Afrotheria; xen, Xenarthra; mar, Marsupialia; and mon, Monotremata.
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oxisome proliferator activated receptor γ protein that is a
master regulator of adipocyte differentiation [32]. Expres-
sion of APMAP was reported to be strongly correlated
with hepatic-specific metastasis in patients with metastatic
colorectal cancer [33]. A recent study demonstrated thatAPMAP is a negative regulator of amyloid-beta (Aβ) pro-
duction through its interaction with amyloid precursor pro-
tein and γ-secretase [34]. Although APMAP seems to be
involved in various biological processes in humans, the mo-
lecular function directly associated with the human-specific
N-glycosylation site in APMAP is yet to be determined.
Table 2 Molecular evolutionary analysis of APMAP, CD166, and thyroglobulin
Protein Model ln L ω 2Δl P value Positively selected sitesa
APMAP Branch
models
M0 (one ratio) −2042.0968 ω0 = 0.07385
Free ratio −2035.7572 See Additional file 4 (M0 vs Free ratio)
12.6792
0.1234
Two ratio −2038.4530 ω0 = 0.05733,
ω1 = 999.000





Model A −2038.4530 ω0 = 0.05732, ω1 = 1,
ω2 = 999.000
Val-100, Asn-196
Null model A −2039.0253 ω0 = 0.05746,
ω1 = 1, ω2 = 1





M0 (one ratio) −2713.8934 ω0 = 0.09913
Free ratio −2709.9951 See Additional file 5 (M0 vs Free ratio)
7.7966
0.4536
Two ratio −2713.8904 ω0 = 0.09991,
ω1 = 0.09134





Model A −2713.8934 ω0 = 0.09913,
ω1 = 1, ω2 = 1
Asn-91
Null model A −2713.8934 ω0 = 0.09913,
ω1 = 1, ω2 = 1





M0 (one ratio) −15128.0999 ω0 = 0.35639
Free ratio −15121.3529 See Additional file 6 (M0 vs Free ratio)
13.4941
0.09595
Two ratio −15124.3983 ω0 = 0.33454,
ω1 = 0.78473





Model A −15103.5548 ω0 = 0.000, ω1 = 1,
ω2 = 3.59382
Asn-76, Ser-633, Ser-734, Asn-775,
Met-911, Ser-913, Gly-1061, Ser-1140,
Thr-1204, Met-1242, Thr-1498, Arg-1646,
His-1669, Arg-1691, Asp-1795, His-2486,
Arg-2530, Asn-2616, Leu-2632, Glu-2702,
Thr-2727, Thr-2765
Null model A −15104.1308 ω0 = 0.000, ω1 = 1,
ω2 = 1
(Model A vs Null
model A) 1.1520
0.2831
aHuman-specific N-glycosylation sites are in bold. See Additional files 4, 5, and 6 for details.
**P < 0.05.
Kim and Hahn BMC Bioinformatics  (2015) 16:29 Page 5 of 12Human-specific N-glycosylation site Asn-91 in CD166
The human CD166, which is also known as activated
leukocyte cell adhesion molecule (ALCAM), has 10 N-
glycosylation sites. The residue Asn-91 is found in humans
but not in other euarchonts; thus, this residue evolved after
the divergence of humans and chimpanzees (Figure 3B).
Most other mammals have a Ser residue at this pos-
ition. However, some Glires and Laurasiatheria spe-
cies, especially whales and ruminants, independently
acquired a consensus sequence for N-glycosylation at
this position.
Multiple alignment of full-length CD166 proteins from
human, chimpanzee, gorilla, orangutan, gibbon, and rhe-
sus macaque genomes revealed that the Asn-91 is only
residue that differs between humans and chimpanzees
(Additional file 5). Although the Asn-91 is human-specific,
all the LRTs (M0 versus free ratio model, M0 versus tworatio model, and model A versus null model A) were insig-
nificant (Table 2 and Additional file 5), implying that there
has been no statistically noticeable positive selection on
the human CD166. Interestingly, the human-specific N-
glycosylation site Asn-91 was still inferred to be under
positive selection with overall probability of 0.613, sug-
gesting the acquisition of this site and its N-glycosylation
might have an effect on the function of human CD166
proteins.
CD166 binds to the T-cell differentiation antigen CD6
and may play a role in the binding of T and B cells to ac-
tivated leukocytes, as well as in interactions between
cells of the nervous system [35]. CD166 is composed of
five extracellular immunoglobulin (Ig)-like domains: two
Ig-like V-type domains and three Ig-like C2-type domains.
The human-specific N-glycosylation site Asn-91 is located
in the first Ig-like V-type domain, which mediates the
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on CD166 have focused on its cancer-related functions
such as invasion, migration, and adhesion [37,38]. How-
ever, recent studies show that CD166 is also involved in
axon growth in neuronal cells such as retinal ganglion
cells and dorsal root ganglion cells [39,40]. Therefore, it is
possible that the gain of the Asn-91 N-glycosylation site in
CD166 might be involved in the evolution of novel pheno-
types in nervous system development, as well as in im-
mune response and cell adhesion processes, which must
be validated experimentally.
Human-specific N-glycosylation site Asn-76 in
thyroglobulin
Thyroglobulin is the precursor of the thyroid hormones
T4 and triiodothyronine (T3), both of which regulate
metabolism in humans [41-43]. The human thyroglobulin
has 17 N-glycosylation sites; Asn-76, which becomes Asn-57
in the mature form of thyroglobulin, is a human-specific
N-glycosylation site: most other mammals have Asp
or Glu at this position (Figure 3C). Interestingly, multiple
alignment of thyroglobulin orthologs from humans, chim-
panzees, gorillas, orangutans, gibbons, and rhesus ma-
caques revealed additional 20 amino acid positions with
human-specific substitution (Additional file 6).
To test if the thyroglobulin has been under positive se-
lection during human evolution, ω ratios across different
branches and sites of the selected primate phylogeny
were estimated (Table 2 and Additional file 6). The LRT
comparing M0 and free ratio model was not significant.
However, the LRT comparing M0 and two ratio model
was highly significant (P = 0.006511), implying the hu-
man thyroglobulin has evolved at different rate com-
pared to other primates. The estimated ω ratio for the
human branch (ω1) using two ratio model was 0.78473,
while ω0 for other branches was 0.33454 (see Additional
file 6 for details), suggesting a slightly accelerated nonsy-
nonymous substitution during human evolution.
Inference of positively selected sites in human thyro-
globulin using model A showed that the 21 aforementioned
amino acid positions might have been under positive selec-
tion although the LRT comparing model A and null model
A was not significant. In spite of statistical insignificance,
the acquisition of novel N-glycosylation site Asn-76,
together with other 20 human-specific amino acid substi-
tutions, might have a significant effect on the thyroid hor-
mone metabolism in humans.
The thyroglobulin protein precursor itself has no bio-
logical function but serves as a chemical platform for thy-
roid hormone production. When the two N-glycosylation
sites in its N-terminal region, including the human-
specific Asn-76, were deglycosylated by peptide-N4-(N-
acetyl-β-glucosaminyl)-asparagine amidase, T4 production
decreased by half compared to that seen with the normalprotein [44]. Therefore, proper N-glycosylation modifications,
including those at the human-specific site, in thyroglobu-
lin are crucial for normal T4 production and the control
of metabolism. It has been suggested that humans and
chimpanzees differ with respect to their thyroid hor-
mone metabolism [45]. Interestingly, compared to chim-
panzees, humans have a higher T4 plasma concentration,
which may be implicated in the origins of human
intelligence [46].
Novel N-glycosylation sites shared by other animals
Of the 112 novel N-glycosylation sites in human proteins,
109 sites were shared by other animals. For example,
12 N-glycosylation sites were shared by all apes, indicating
that this site appeared in the common ancestor of apes.
The Asn-480 of pappalysin-1 (also known as pregnancy-
associated plasma protein-A), which is N-glycosylated in
humans [47], is shared by all apes examined (Figure 4A);
in contrast, all the other mammals, even Marsupialia and
Monotremata species, have an Asp residue at this pos-
ition. Pappalysin-1 has metalloproteinase activity and spe-
cifically cleaves insulin-like growth factor-binding proteins
[48,49]; it is present at high concentration in maternal
blood during pregnancy and is essential for normal fetal
development [50]. The serum pappalysin-1 concentration
frequently increases in patients with severe sepsis and ap-
pears to be associated with sepsis-related myocardial dys-
function [51]. However, there is no comprehensive study
of whether the gain of Asn-480 in apes is associated with
these phenotypes.
There are 12 N-glycosylation sites that might have arisen
in the common ancestor of apes. One is Asn-113 in the
thyrotropin receptor, or thyroid-stimulating hormone
receptor (TSHR) (Figure 4B). The THSR responds to
thyroid-stimulating hormone (also known as thyrotropin)
and stimulates the production of T4 and T3 in the thyroid
gland [52]. Human THSR has six N-glycosylation sites:
Asn-113 is specific to apes, and the other five are con-
served in other mammals. However, a mutated TSHR in
which N-glycosylation at Asn-113 had been disrupted had
the same expression level and function as the wildtype
TSHR; thus, Asn-113 N-glycosylation may not be im-
portant for TSHR function [53]. Therefore, gain of N-
glycosylation at Asn-113 may be neutral or have a
function yet to be determined.
The UDP-glucuronosyltransferase 1–9 (UD19) Asn-344
is one of 45 N-glycosylation sites that are shared by sim-
ians (apes and monkeys; Figure 4C). Nonsimian mammals
have a Lys residue at this position. UD19, which is also
known as UDP glucuronosyltransferase 1 family, polypep-
tide A9, is involved in the conjugation and elimination
of toxic xenobiotic and endogenous compounds [54,55].
Unglycosylation of UD19 resulted in the inhibition of
proper protein folding and the impairment of glucuronidation
Figure 4 Multiple sequence alignments of N-glycosylation sites that arose during human evolution. The N-glycosylation sites and the
surrounding regions for pappalysin-1 (A), TSHR (B), and UD19 (C) proteins are presented. See Figure 3 for further details.
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human UD19 protein [56]. UD19 is one of nine func-
tional isoforms produced by the alternative utilization
of the first nine exons in the UGT1A gene locus [57].
Because Asn-344 is located in the common exon 5, not
only UD19 but also eight other isoforms of UDP glucuro-
nosyltransferase 1 enzyme have this novel N-glycosylation
site [56].Discussion
Previously, it has been suggested that the gain of novel
protein PTM sites such as ubiquitylation sites may be
associated with the acquisition of novel phenotypes dur-
ing human evolution by modulating the activity or net-
work of proteins [16]. It is also highly probable that
gains of novel N-glycosylation sites may result in func-
tional modification of proteins and phenotypic changes
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containing experimentally verified N-glycosylation sites
and their orthologous mammalian proteins were system-
atically compared. As a result, 112 novel N-glycosylation
sites were identified in 91 proteins that newly appeared
during human evolution after the Euarchonta lineage di-
verged from the Glires lineage. It must be noted that
most of these novel N-glycosylation sites were obtained
by high-throughput mass spectrometry. The presence of
these modifications must be further scrutinized by con-
ventional molecular biology techniques.
Not all the novel N-glycosylation sites described in this
study may have resulted in functional innovation. Some
of them might have appeared as a result of random gen-
etic drift and be functionally neutral. Nevertheless, some
of them could have conferred selective advantage during
human evolution and be fixed in the human genome.
One such example identified in this study is the novel
N-glycosylation site in UD19, which is involved in the
elimination of potentially toxic xenobiotics and endogen-
ous compounds. UD19 acquired the novel N-glycosylation
site Asn-344 during the evolution of the common an-
cestor of apes and monkeys (see Figure 4C). When
the N-glycosylation at Asn-344 is abolished, folding is
inhibited in UD19, and its glucuronidase activity is re-
duced [54]. Therefore, glycosylation at Asn-344 is re-
quired for proper folding and activity of UD19. It is
possible that ancestral simian primates required better
defense mechanisms against toxic compounds introduced
into their systems by environmental or dietary shifts. The
acquisition of a new N-glycosylation site in UD19 might
have conferred improved xenobiotics metabolism to apes
and monkeys, although there is no direct evidence for this
hypothesis.
The three human-specific N-glycosylation sites are
particularly interesting (see Table 1 and Figure 3). The
residue Asn-196 in APMAP is the first of the three
human-specific N-glycosylation sites, which was inferred
to be positively selected with an extremely high prob-
ability in humans (see Table 2 and Additional file 4). The
human APMAP has been reported to be involved in a
variety of biological processes including adipocyte differ-
entiation, hepatic-specific metastasis in cancer, and in-
hibition of Aβ production [32-34]. The fact that APMAP
is implicated in adipocyte differentiation is particularly
interesting because humans and great apes exhibit large
differences in adipose tissue and fatty acid storage, and
these differences may be associated with the develop-
ment of subcutaneous fat and even in brain development
[58,59]. Therefore, the molecular functional study of
human-specific sequence changes in proteins such as
APMAP, which are associated with adipose tissue and
lipid metabolism, may reveal the molecular mechanisms
for the evolution of these traits.The human CD166 protein has two Ig-like V-type do-
mains and three Ig-like C2-type domains (Figure 5A)
and functions as a cell adhesion molecule. The human-
specific N-glycosylation site Asn-91, which was inferred
to be positively selected (see Table 2 and Additional file
5), is located within the first Ig-like V-type domain,
which is responsible for protein–protein interactions
[35-37]. The addition of a bulky glycan moiety to this
domain may change its structural profile and thus affect
cell–cell adhesion activity or ligand specificity. The most
interesting function of CD166 is its involvement in axon
growth in neuronal cells [39,40]. Of the 583 amino acid
residues in CD166, only the residue at position 91 differs
between humans and chimpanzees; therefore, the emer-
gence of Asn-91 and its N-glycosylation might be associated
with evolution of human-specific phenotypes, probably
in the nervous system, which must be determined
experimentally.
The human thyroglobulin, which serves as a precursor
molecule for the thyroid hormones T4 and T3, has a
human-specific N-glycosylation site Asn-76. The human
thyroglobulin contains 11 thyroglobulin type-1 domains,
which are involved in the control of proteolytic degrad-
ation [60]. The human-specific Asn-76 is located within
the first thyroglobulin type-1 domain (Figure 5B). The
Asn-76 was inferred to be positively selected during hu-
man evolution, along with the other 20 positions (see
Table 2 and Additional file 6). Removal of the glycan group
from the Asn-76 reduced thyroid hormone production, es-
pecially T4 production [44]; thus, the gain of Asn-76 and
its N-glycosylation, together with the other 20 putatively
adaptive amino acid changes, may be implicated in the in-
creased T4 concentration present in humans as compared
to chimpanzees. It is possible that the additional glycan
moiety may confer increased resistance to the proteolytic
degradation of thyroglobulin proteins and thus lead to in-
creased thyroid hormone production. It is very interesting
that the T4 concentration in humans is higher than that in
chimpanzees [45], as elevated T4 production may have
caused the modification of human physiology in response
to selection pressures in a specific environment: specific-
ally, it has been proposed that an altered thyroid hor-
mone metabolism might have been beneficial for early
humans in the savannah environment, as they practiced
persistence hunting and thus had large energy require-
ments [46].
Losses of N-glycosylation sites during human evolu-
tion are also very interesting. Some human diseases have
been reported to be caused by the loss of N-glycosylation
sites [61]. To find cases where ancestrally conserved
N-glycosylation sites were lost during human evolution, a
large amount of N-glycosylation data collected from
animals distantly related to humans is required. The N-
glycoproteome data obtained from mouse tissues and
Figure 5 Schematic domain organizations of CD166 (A) and thyroglobulin (B). The N-glycosylation sites are indicated with lollipops, and
human-specific sites are indicated in red. The domain organizations are derived from the UniProt database; the accession numbers are
[Swiss-Prot:Q13740] (CD166) and [Swiss-Prot:P01216] (thyroglobulin).
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be an ideal dataset for this analysis [62]. With a simple
modification, the procedure described in this study could
be used to analyze these data for the identification of
N-glycosylation sites that were lost during human evolu-
tion and their possible phenotypic implications.
Conclusions
We have devised and applied a bioinformatics method
to identify the acquisition of N-glycosylation sites during
human evolution. We propose that the acquisition of novel
N-glycosylation sites may play a role in the development of
lineage-specific phenotypes during evolution. Thus, the
cases identified in this study may provide a useful resource
for molecular functional analyses in search of human traits
acquired during evolution.
Methods
Human N-glycosylation site data
The N-glycosylation sites in human proteins were ob-
tained from the UniProt database (as of 13 November,
2013). The feature table of the UniProt records was
scanned to collect entries with experimentally identified
N-glycosylation sites. Specifically, the lines starting with
“FT” followed by the “CARBOHYD” tag were examined
for whether they contained a term “N-linked (GlcNAc…)”,
which would indicate that the protein was N-glycosylated.
Sites without experimental evidence, labeled as “potential”,
“by similarity”, “partial”, or “probable”, were excluded. As
a result, 2,534 N-glycosylation sites from 1,027 human
proteins were obtained.
Mammalian orthologous proteins
Mammalian orthologs of the human glycosylated pro-
teins were obtained from the UCSC Genome Browser
Database (http://genome.ucsc.edu). The “CDS FASTAalignment from multiple alignments” data, derived from
the “multiz100way” alignment data prepared from 100
vertebrate genomes [25], were downloaded using the Table
Browser tool of the UCSC Genome Browser. Protein se-
quences from 62 mammalian species were extracted from
these alignment datasets. The selected mammalian spe-
cies include humans, 12 other Euarchonta species (chim-
panzees, gorillas, orangutans, gibbons, rhesus macaques,
crab-eating macaques, baboons, green monkeys, marmo-
sets, squirrel monkeys, bushbabies, and treeshrews), 13
Glires species (lesser Egyptian jerboas, prairie voles, Chinese
hamsters, golden hamsters, mice, rats, naked mole-
rats, guinea pigs, chinchillas, brush-tailed rats, rabbits,
and pikas), 25 Laurasiatheria species (pigs, alpacas, Bactrian
camels, dolphins, killer whales, Tibetan antelopes, cows,
sheep, goats, horses, white rhinoceroses, cats, dogs, fer-
rets, pandas, Pacific walruses, Weddell seals, black flying-
foxes, megabats, David’s myotis bats, microbats, big brown
bats, hedgehogs, shrews, and star-nosed moles), six
Afrotheria species (elephants, cape elephant shrews,
manatees, cape golden moles, tenrecs, and aardvarks),
one Xenarthra species (armadillos), three Marsupialia
species (opossums, Tasmanian devils, and wallabies), and
one Monotremata species (platypuses). Additional file 1
contains detailed information on species and genome
assemblies.
Computational screening for candidate novel
N-glycosylation sites in human proteins
The total number of experimentally identified N-glycosylation
sites collected from human proteins was 2,534. To identify
mammalian proteins that were orthologous to each of the
human N-glycosylated proteins, the “multiz100way” align-
ment data containing 57,289 alignment sets were analyzed
(see Figure 1 for the overall procedure). There were 1,027
orthologous protein datasets comprising 2,534 human
Kim and Hahn BMC Bioinformatics  (2015) 16:29 Page 10 of 12N-glycosylation sites. From each dataset, sequences of 62
mammalian species were extracted and realigned using
MUSCLE (http://www.drive5.com/muscle) [63]. Then,
each modification site in the alignment was analyzed,
and cases where more than 30% of non-Euarchonta spe-
cies had an N-glycosylation motif, which might represent
ancestrally conserved sites, were discarded; cases where
only a small number of sequences were aligned were also
discarded. A total of 184 sites in 130 protein alignments
were retained after this computational screening step and
subjected to in-depth semimanual inspection.
Manual inspection to select novel N-glycosylation sites in
human proteins
As the final step, extensive manual inspection and cur-
ation on the 184 candidate sites was carried out to iden-
tify highly plausible cases of gains of N-glycosylation
sites in the human lineage. Datasets showing the follow-
ing conditions were filtered out: cases where the human
sequence of UniProt database was different from that of
UCSC in three or more amino acid sequence residues be-
cause of a possible paralogous relationship; cases where
the N-glycosylated site was different from the consensus
Asn-X-Ser/Thr; cases where the human N-glycosylation
occurred only in a rare variant or mutant allele; or cases
where the chimpanzee protein sequence was not included.
In each dataset, sequences containing many gaps in align-
ment were removed from the dataset to retain only high
quality sequences.
As the final result, 112 novel N-glycosylation sites in
91 human proteins were identified. Then, multiple alignments
were constructed to determine when the N-glycosylation
motifs first appeared. The possible functional conse-
quences of the novel N-glycosylation site were then
assessed by comprehensive literature survey and se-
quence analysis.
Molecular evolutionary analysis
Full-length protein and coding sequences of APMAP,
CD166, and thyroglobulin were collected from humans,
chimpanzees, gorillas, orangutans, gibbons, and rhesus
macaques. Human cDNA RefSeq sequences were ob-
tained from the National Center for Biotechnology In-
formation (NCBI) (http://www.ncbi.nlm.nih.gov/refseq):
accession numbers are [NCBI:NM_020531] (APMAP),
[NCBI:NM_001627] (CD166), and [NCBI:NM_003235]
(thyroglobulin). For chimpanzee, gorilla, orangutan, gib-
bon, and rhesus macaque orthologs, genome assemblies
(panTro4, gorGor3, ponAbe2, nomLeu3, and rheMac3,
respectively) were searched using each of human cDNA
sequences at the UCSC Genome Browser Database.
Exons, which were predicted from genomic segments,
were assembled into a virtual cDNA and then conceptu-
ally translated to get a protein sequence. Some exons,which were missing in the current genome assembly,
were obtained by assembling whole genome shotgun
reads by searching the NCBI Sequence Read Archive
(SRA) with SRA-BLAST server (http://www.ncbi.nlm.
nih.gov/sra).
The ratio of nonsynonymous to synonymous substi-
tution rates (dN/dS, ω) was estimated by a likelihood
method implemented in the codeml program of the
PAML package (version 4.8a) [64]. To detect possible
accelerated evolution in human proteins, we employed
“branch models” that allow the ω ratio to vary among
branches in phylogeny [27]; M0 (one ω ratio for all line-
ages), free ratio (one ω ratio for each branch), and two
ratio (ω1 for the human branch and ω0 for the other
branches). To infer positively selected sites in human
proteins, we used “branch-site models” that allow the ω
ratio to vary among both sites and lineages [26,28]; model
A (ω is left to vary) and null model A (ω is fixed to 1). To
compare the fit of nested models, the likelihood ratio test
(LRT) was performed [27]. P values were obtained using
the “chi2” program in the PAML package. Protein and
coding sequences, tree files, control files, and major result
files for APMAP, CD166, and thyroglobulin are provided
in Additional files 4, 5, and 6, respectively.
Additional files
Additional file 1: List of mammalian species and genome assemblies.
Additional file 2: List of novel N-glycosylation sites.
Additional file 3: Sequence alignments of novel N-glycosylation sites.
Additional file 4: Molecular evolutionary analysis of APMAP.
Additional file 5: Molecular evolutionary analysis of CD166.
Additional file 6: Molecular evolutionary analysis of thyroglobulin.
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